

A scoping review to understand that state of the science of scale-up of cancer control interventions in low- and middle-income countries

15TH ANNUAL

CONFERENCE

ON THE SCIENCE OF DISSEMINATION AND IMPLEMENTATION IN HEALTH

Tara M. Friebel-Klingner*¹, Gloria Guevara Alvarez*², Lydia E Pace³, Keng-Yen Huang⁴, Maria E Fernández⁵, Donna Shelley², Anne Rositch**¹

¹ Department of Epidemiology Johns Hopkins Bloomberg School of Public Health 615 N. Wolfe Street, Baltimore, MD 21205

² Department Public Health Policy and Management, School of Global Public Health, New York University, 708 Broadway, New York, NY, 10003

³ Brigham and Women's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115

⁴ Center for Early Childhood Health & Development (CEHD), Department of Population Health, NYU Langone Health 227 East 30th Street, 7th Floor, New York, NY 10016

⁵ Health Promotion and Behavioral Sciences, and Center for Health Promotion and Prevention Research, The University of Texas Health Science Center at Houston (UTHealth) School of Public Health Houston 7000 Fannin Street, Suite 20, Houston, TX 77030



RESEARCH OBJECTIVE

- Cancer deaths in low-resource settings will nearly double by 2040.
- Evidence-based interventions (EBIs) for cancer early detection and prevention (e.g., breast and cervical cancer screening, human papilloma virus vaccinations) have lowered cancer-related mortality in high-income countries and have been tested at limited scale in low-to-middle income countries (LMIC).
- However, LMICs face barriers to scaling-up EBIs in under-resourced health systems. This reflects, in part, the dearth of evidence for strategies to scale cancer control interventions in LMICs.
- Thus, we conducted the first scoping review to delineate the state of scale-up of cancer control EBIs in LMICs, including cancer types targeted, implementation strategies used, and barriers related to scale-up.**

METHODS


We searched six electronic databases to identify literature in English between 2012-2022.

Studies were included if they reported scale-up or met one of two definitions:

- Described deliberate efforts to increase the impact of EBIs to benefit more people and to foster policy and program development or
- Assessed the ability of an efficacious small scale health intervention to be successfully expanded under real-world conditions.

Two independent reviewers screened citations for inclusion. Data abstraction was performed by one reviewer and verified by a second reviewer.

PRISMA diagram




RESULTS

- Our search yielded 6599 eligible abstracts and **24 studies were ultimately included.**
- 54.2% (n=13) studies explicitly mentioned “scale-up”.
- All 24 studies involved stakeholder relationships. Multilevel relationships reported included: international partners, national partners, national Ministry of Health (MoH), regional partners, community partners, international pharmaceutical partners, and/or academic partners.
- 20.8% (n=5) were low-income countries, 33.3% (n=8) were lower-middle income countries, 37.5% (n=9) were upper-middle income countries, and 8.3% (n=2) of studies included more than one country.
- Most studies (n=17, 70.8%) scaled-up early detection/secondary prevention EBIs.
- Two studies utilized Implementation Science (IS) frameworks (Consolidated Framework for Implementation Research and RE-AIM) to scale up.
- Commonly reported methods were synonymous with IS strategies.
- Many “implementation science” outcomes were mentioned, including feasibility, acceptability, and sustainability.
- Barriers identified included prohibitive costs and infrastructure issues.

Implementation Science Scale-up Strategies

Implementation Strategies Utilized to Scale Up	# studies using strategy (%)
Train and educate stakeholders	19 (79.2%)
Change infrastructure	16 (66.7%)
Engage consumers	14 (58.3%)
Develop stakeholder interrelationships	12 (50.0%)
Use evaluative and iterative strategies	10 (41.7%)
Utilize financial strategies	6 (25.0%)
Provide interactive assistance	5 (20.8%)
Adapt and tailor to context	3 (12.5%)

Target Cancer of the EBI for 24 studies



Implementation Science Outcomes

IS outcomes mentioned by name	N	Percent (%)
Studies referring to Imp Sci Outcomes	22	88
Re-Aim outcomes- # total studies	7	29.2
Reach	3	12.5
Effectiveness	2	8.3
Adoption	4	16.7
Implementation	1	4.2
Maintenance	1	4.2
Proctor - # total studies	22	88
Fidelity	3	12.5
Adherence	2	8.3
Acceptability	9	37.5
Appropriateness	1	4.2
Feasibility	10	41.7
Penetration	6	25.0
Implementation cost	2	8.3
Sustainability	9	25.0
Adaptability	2	8.3

REFERENCES

• IARC. The Global Cancer Observatory. 2021; <https://jamaneetwork.com/journals/jama/article-abstract/2782998>. Accessed August 24.

• Waltz TJ, Powell BJ, Matthieu MM, et al. Use of concept mapping to characterize relationships among implementation strategies and assess their feasibility and importance: results from the Expert Recommendations for Implementing Change (ERIC) study. *Implementation Science*. 2015;10(1):1-8.

• Proctor F, Silmere H, Raghavan R, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. *Adm Policy Ment Health*. Mar 2011;38(2):65-76.

• Powell BJ, Waltz TJ, Chinman MJ, et al. A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project. *Implementation Science*. 2015;10(1):1-14.

• Wang Y, Yu YH, Shen K, et al. Cervical cancer screening and analysis of potential risk factors in 43,567 women in Zhongshan, China. *Asian Pac J Cancer Prev*. 2014;15(2):671-676.

• Shikha S, Smita J, Nayanjeet C, et al. Experience of a "Screen and treat" program for secondary prevention of cervical cancer in Uttar Pradesh, India. *J Obstet Gynaecol Res*. Feb 2020;46(2):320-327.

• Chary AN, Rohloff PJ. Major challenges to scale up of visual inspection-based cervical cancer prevention programs: the experience of Guatemalan NGOs. *Glob Health Sci Pract*. Aug 2014;2(3):307-317.

• Kumar S, Usmanova G, Nair TS, et al. Implementation of a large-scale breast cancer early detection program in a resource-constrained setting: real-world experiences from 2 large states in India. *Cancer*. Feb 9 2022.

• Johnson LG, Ramogola-Masire D, Teitelman AM, Jemott JB, Buttenheim AM. Assessing Nurses' Adherence to the See-and-Treat Guidelines of Botswana's National Cervical Cancer Prevention Programme. *Cancer Prev Res (Phila)*. Mar 2020;13(3):329-336.

• Binagwaho A, Ngabo F, Wagner CW, et al. Integration of comprehensive women's health programmes into health systems: cervical cancer prevention, care and control in Rwanda. *Bull World Health Organ*. Sep 1 2013;91(9):697-702.

• Wu TY, Hoffman JL. Breast Cancer Early Detection: An Academic-Community Partnership in the Philippines. *Clin J Oncol Nurs*. Oct 1 2019;23(5):547-551.

• Oluwole D, Kraemer J, Pink Ribbon Red R. Innovative public-private partnership: a diagonal approach to combating women's cancers in Africa. *Bull World Health Organ*. Sep 1 2013;91(9):691-696.

• Chigbu CO, Onyebuchi AK, Onyeka TC, Odugu BU, Dim CC. The impact of community health educators on uptake of cervical and breast cancer prevention services in Nigeria. *Int J Gynaecol Obstet*. Jun 2017;137(3):319-324.

• Alfaro K, Maza M, Felix JC, et al. Outcomes for Step-Wise Implementation of a Human Papillomavirus Testing-Based Cervical Screen-and-Treat Program in El Salvador. *ICO Glob Oncol*. Oct 2020;6:1519-1530.

• Li X, Qian M, Zhao G, et al. The performance of a community-based colorectal cancer screening program: Evidence from Shanghai Pudong New Area, China. *Prev Med*. Jan 2019;118:243-250.

• Korn AK, Muzingwani L, O'Brian G, et al. Cervical cancer screening and treatment, HIV infection, and age: Program implementation in seven regions of Namibia. *PLoS One*. 2022;17(2):e0263920.

• Lemoine M, Shimakawa Y, Njie R, et al. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. *Lancet Glob Health*. Aug 2016;4(8):e559-567.

• Arrosio S, Paulino M, Thouyret L, Laudi R, Campanera A. Evaluation of scaling-up of HPV self-collection offered by community health workers at home visits to increase screening among socially vulnerable under-screened women in Jujuy Province, Argentina. *Implement Sci*. Feb 13 2017;12(1):17.

• Khozaim K, Orang'o E, Christofferson-Deb A, et al. Successes and challenges of establishing a cervical cancer screening and treatment program in western Kenya. *Int J Gynaecol Obstet*. Jan 2016;124(1):12-18.

• Holme F, Jeronimo J, Maldonado F, et al. Introduction of HPV testing for cervical cancer screening in Central America: The Scale-Up project. *Prev Med*. Jun 2020;135:106076.

• Queiroga Y, Furlane G, Fruhuf T, et al. Expanding the Single-Visit Approach for Cervical Cancer Prevention: Successes and Lessons From Burkina Faso. *Glob Health Sci Pract*. Jun 17 2018;6(2):288-298.

• Boni S, Tchounga B, Comeo K, et al. Assessment of the scale-up of cervical cancer screening in Abidjan stratified by HIV status. *Int J Gynaecol Obstet*. Nov 2019;147(2):246-251.

• Mwanahamuntu MH, Sahasrabudhe VV, Blevins M, et al. Utilization of cervical cancer screening services and trends in screening positivity rates in a "screen-and-treat" program integrated with HIV/AIDS care in Zambia. *PLoS One*. 2013;8(5):e74607.

• Borja-Aburto VH, Gonzalez-Anaya JA, Davila-Torres J, Rascon-Pacheco RA, Gonzalez-Leon M. Evaluation of the impact on non-communicable chronic diseases of a major integrated primary health care program in Mexico. *Fam Pract*. Jun 2016;33(3):219-225.

• So C, Gimbel S, Chilundo B, Muchanga V, Matsinhe L, Sherr K. Human papillomavirus vaccine delivery in Mozambique: identification of implementation performance drivers using the Consolidated Framework for Implementation Research (CFIR). *Implement Sci*. Dec 13 2018;13(1):151.

• Kumar S, Usmanova G, Nair TS, et al. Implementation of a large-scale breast cancer early detection program in a resource-constrained setting: real-world experiences from 2 large states in India. *Cancer*. May 1 2022;128(9):1757-1766.

Barriers to Scale-up Identified

Barrier	Example
Individual-level	
Patients' fidelity (follow-up) to program	<ul style="list-style-type: none"> Poor communication about follow-up visits from providers to patients Commuting costs and due to poor communication Difficulties tracking referred patients Expansion of participants and program Missed repeat cryotherapy at one-year for those who tested VIA positive Embarrassment by female patients being screened by a male doctor
Lack of information	Little knowledge about the disease: <ul style="list-style-type: none"> HPV and the HPV vaccine Breast cancer
Low participant compliance	<ul style="list-style-type: none"> Low screening uptake or adherence Varied compliance within specific subgroups (higher socioeconomic status of the participants in terms of education levels and employment status)
Lack of access and resources	<ul style="list-style-type: none"> High costs of service and financial concerns No insurance
Health systems-level	
Poor infrastructure to support a program	<ul style="list-style-type: none"> Lack of ability to see referral through after screening for VIA, leading to program failure to treat VIA positive eligible women Lack of pathology related infrastructure like lack of histopathologists
Inaccurate reporting of program use	<ul style="list-style-type: none"> Varied performance of the screening across geographic areas not clearly reported and under counting patients who completed follow up treatment,
Resource allocation and use	<ul style="list-style-type: none"> Lack of personnel /providers (at different levels including supervision staff, specialized personnel like gynecologist) available for the delivery of the intervention Fatigue among existing staff; staff turnover Unavailability of the coordinating nurse, especially during Ramadan holidays Low provider: patient ratio in urban areas, impacted number of patients screened and treated Lack of supplies and specific equipment needed to perform screen and treatment; stock-outs of key supplies including diagnostic kits (i.e., cryotherapy machine, gas for machine)
Community-level	
Link to community	<ul style="list-style-type: none"> Targeting and reaching the eligible group Lack of community health care worker ties at a blood bank compared to the community Community transformations, due to high rates of migration out of service delivery area
Values system/alignment with values	<ul style="list-style-type: none"> The need for an HPV vaccine not in line with controversial issues such as virginity, which leads to refusal to vaccination. Identifying a need to connect with churches about health education.

CONCLUSION

- As cancer is increasing in LMICs, there is a scarcity of scaled-up cancer control EBIs.
- We synthesized barriers at the individual-, health systems-, and community-levels.
- When scaling-up, emphasis should be on system level barriers, as a successful program at scale is dependant on a streamlined and efficient health system.
- Utilizing IS strategies can address many of the multilevel barriers identified.
- When scaling-up EBIs in LMICs, utilizing multiple disciplines, including IS, may help synthesize knowledge across studies and accelerate scale-up progress.

ACKNOWLEDGEMENTS

Thank you to Consortium for Cancer in Implementation Science (CCIS) for funding this public good.

CONTACT INFO

Tara M. Friebel-Klingner
tfriebe1@jhu.edu
 Gloria Guevara Alvarez
gga2009@nyu.edu